<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218491</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-19903-1</org_study_id>
    <secondary_id>R01DA019903</secondary_id>
    <secondary_id>R01-19903-1</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218491</nct_id>
  </id_info>
  <brief_title>Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1</brief_title>
  <acronym>NAC</acronym>
  <official_title>A Controlled Trial of N-Acetylcysteine (NAC) for Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, no effective drug treatment exists for cocaine dependence. Glutamate levels are
      disrupted with long-term cocaine use. N-acetyl cysteine (NAC) is a drug that is metabolized
      by the body to form cysteine, an active compound that normalizes glutamate levels. The
      purpose of this study is to determine the safety and effectiveness of NAC in treating cocaine
      dependent individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, no effective pharmacological treatment exists for cocaine dependence. Long-term
      use of cocaine disrupts normal glutamate levels. If addicts stop using cocaine, glutamate
      levels drop, which encourages addicts to continue seeking the drug. NAC is a drug that
      increases intracellular cysteine levels, which in turn leads to normalization of glutamate
      levels. Currently, NAC is used for the treatment of cystic fibrosis, heart disease, and
      acetaminophen overdose. Since NAC has the capability of restoring normal glutamate levels, it
      holds potential as a treatment for cocaine dependence. The purpose of this study is to
      determine the safety and effectiveness of NAC in treating cocaine dependent individuals. In
      addition, this study will evaluate cocaine craving and withdrawal symptoms in individuals
      taking NAC.

      Participants in this double-blind, placebo-controlled trial will be randomly assigned to
      receive either NAC or placebo. All participants will undergo an initial evaluation, which
      will include a physical examination, an electrocardiogram, blood samples, urine tests, and
      cue reactivity measures. Participants in the NAC group will receive either 600 mg or 1200 mg
      of NAC, two times each day for 8 weeks. In addition, all participants will receive cognitive
      behavioral therapy throughout the study on a weekly basis. Cocaine use will be confirmed by a
      urine drug screen test, three times each week. Participants will be assessed on a number of
      biomedical and psychosocial variables known to influence cocaine treatment outcomes. After
      Week 2, participants will repeat the cue reactivity procedures, which will include measuring
      a participant's craving response when exposed to conditioned reminders of prior cocaine use.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Achieved Study Compliance</measure>
    <time_frame>8 weeks</time_frame>
    <description>Drug and placebo compliance were measured by urine riboflavin levels. Study compliance was defined as 80% or greater weekly urine riboflavin levels equal to or greater than 1500 ng/ml</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>1200mg N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1200mg N-Acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2400mg N-Acetylcysteine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2400mg N-Acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matching Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>1200mg N-Acetylcysteine</description>
    <arm_group_label>1200mg N-Acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>2400mg N-Acetylcysteine</description>
    <arm_group_label>2400mg N-Acetylcysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>Matching Placebo</description>
    <arm_group_label>Matching Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for cocaine dependence, as determined by a mini-SCID interview

          -  Currently dependent on cocaine

          -  Seeking treatment for cocaine abuse at the time of study entry

          -  Currently uses cocaine by smoking, nasal, or intravenous route of administration.

          -  Stable physical and mental health, as judged by an interview and physical examination

          -  If female, demonstrates a negative pregnancy test and agrees to use an adequate method
             of contraception for the duration of the study

          -  Lives within a 50 mile radius of the research program center and has reliable
             transportation

        Exclusion Criteria:

          -  Meets DSM-IV criteria for dependence on any psychoactive substance other than cocaine,
             alcohol, nicotine, or marijuana

          -  Physiological dependence on alcohol, which requires medical detoxification

          -  History of significant liver, kidney, endocrine, cardiac (e.g., arrhythmia requiring
             medication, angina pectoris, myocardial infarction), stroke, seizure, neurological,
             non-drug-related psychiatric, gastrointestinal, pulmonary, hematologic, or metabolic
             disorders (e.g., homocystinuria)

          -  History of an adverse reaction to cocaine, including loss of consciousness, chest
             pain, psychosis, or seizure

          -  History of adverse reaction or hypersensitivity to N-acetyl cystine (NAC), or a
             similar drug

          -  Significant active medical or psychiatric illness that might inhibit the ability to
             complete the study

          -  Active high blood pressure, defined as a mean of three sitting blood pressure readings
             of 145/95 or higher within a 10-day period

          -  History of or current asthma

          -  Occasional or daily use of albuterol or other beta-agonist inhalers

          -  Use of carbamazepine, phenytoin, nitrous oxide, methotrexate, 6 azauridine triacetate,
             or nitroglycerin within the 2 weeks prior to study entry

          -  Use of very large doses of folate, cyanocobalamine (vitamin B12), or pyridoxine
             (vitamin B6) as prescribed by a health care professional; individuals taking very
             large doses of these vitamins on a self-initiated basis may enter the study if they
             are willing to stop use 14 days prior to study entry and to use a standard generic
             multiple vitamin instead

          -  Pregnant or breastfeeding

          -  Required by the court to obtain treatment for cocaine dependence

          -  Not seeking treatment for cocaine dependence

          -  Anticipating elective surgery or hospitalization within 20 weeks of study entry

          -  Failure to have a consistent residence for the 4 weeks prior to study entry

          -  History of childhood or adult seizures

          -  Participated in cocaine treatment (clinical or research) within 30 days of study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Malcolm, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>December 21, 2018</results_first_submitted>
  <results_first_submitted_qc>December 21, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2019</results_first_posted>
  <last_update_submitted>December 21, 2018</last_update_submitted>
  <last_update_submitted_qc>December 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of South Carolina</investigator_affiliation>
    <investigator_full_name>Robert Malcolm</investigator_full_name>
    <investigator_title>Professor of Psychiatry, Family Medicine &amp; Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cocaine Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1200mg N-Acetylcysteine</title>
          <description>1200mg N-Acetylcysteine
N-Acetylcysteine: 1200mg N-Acetylcysteine</description>
        </group>
        <group group_id="P2">
          <title>2400mg N-Acetylcysteine</title>
          <description>2400mg N-Acetylcysteine
N-Acetylcysteine: 2400mg N-Acetylcysteine</description>
        </group>
        <group group_id="P3">
          <title>Matching Placebo</title>
          <description>Matching Placebo: Matching Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1200mg N-Acetylcysteine</title>
          <description>1200mg N-Acetylcysteine
N-Acetylcysteine: 1200mg N-Acetylcysteine</description>
        </group>
        <group group_id="B2">
          <title>2400mg N-Acetylcysteine</title>
          <description>2400mg N-Acetylcysteine
N-Acetylcysteine: 2400mg N-Acetylcysteine</description>
        </group>
        <group group_id="B3">
          <title>Matching Placebo</title>
          <description>Matching Placebo
Matching Placebo: Matching Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="38"/>
            <count group_id="B4" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="10.1"/>
                    <measurement group_id="B2" value="43.3" spread="13.6"/>
                    <measurement group_id="B3" value="42.8" spread="8.7"/>
                    <measurement group_id="B4" value="43.2" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Achieved Study Compliance</title>
        <description>Drug and placebo compliance were measured by urine riboflavin levels. Study compliance was defined as 80% or greater weekly urine riboflavin levels equal to or greater than 1500 ng/ml</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1200mg N-Acetylcysteine</title>
            <description>1200mg N-Acetylcysteine
N-Acetylcysteine: 1200mg N-Acetylcysteine</description>
          </group>
          <group group_id="O2">
            <title>2400mg N-Acetylcysteine</title>
            <description>2400mg N-Acetylcysteine
N-Acetylcysteine: 2400mg N-Acetylcysteine</description>
          </group>
          <group group_id="O3">
            <title>Matching Placebo</title>
            <description>Matching Placebo: Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Achieved Study Compliance</title>
          <description>Drug and placebo compliance were measured by urine riboflavin levels. Study compliance was defined as 80% or greater weekly urine riboflavin levels equal to or greater than 1500 ng/ml</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1200mg N-Acetylcysteine</title>
          <description>1200mg N-Acetylcysteine
N-Acetylcysteine: 1200mg N-Acetylcysteine</description>
        </group>
        <group group_id="E2">
          <title>2400mg N-Acetylcysteine</title>
          <description>2400mg N-Acetylcysteine
N-Acetylcysteine: 2400mg N-Acetylcysteine</description>
        </group>
        <group group_id="E3">
          <title>Matching Placebo</title>
          <description>Matching Placebo: Matching Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI Event</sub_title>
                <counts group_id="E1" events="29" subjects_affected="19" subjects_at_risk="40"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="33"/>
                <counts group_id="E3" events="23" subjects_affected="16" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Change in Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle and Joint Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperactivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory event</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatological episode</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Malcolm, MD</name_or_title>
      <organization>Medical University of SC</organization>
      <phone>843-792-1901</phone>
      <email>malcomr@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

